1142 records found.
Jan 24, 2020
ATAI Life Sciences Announces Joint Venture with DemeRx to Develop Ibogaine For Opioid Use Disorder
Jan 24, 2020
Ontario continues to improve access to treatment for children and adolescents living with ADHD who are prescribed INTUNIV XR®*
Jan 23, 2020
Drug of Abuse Testing Market Insights 2013-2020 and Forecast to 2025
Jan 22, 2020
Theramex Acquires Commercial Rights for Oral Contraceptive Zoely
Jan 22, 2020
Rapper Juice WRLD died of accidental opioid overdose: autopsy
Jan 21, 2020
InMed Expands on Announcement of Cannabinol (CBN) Therapeutic Leadership with New Website Content and CEO Interview
Jan 21, 2020
Therapeutic Solutions International Enters into Multi-Million Dollar Master Sales Agreement with Publicly Traded iBrands Corporation
Jan 21, 2020
Introducing Scripta Insights, the Healthcare Tech Company Disrupting the $300B Pharmacy Benefits Industry
Jan 21, 2020
LYPHE Group to Create a Joint Venture With ASX Listed JAYEX
Jan 21, 2020
Cell>Point Expanding Theranostic Clinical Research to Include Platinum and 177Lu Targeted Therapy to Compliment Oncardia® Imaging Platform
Jan 20, 2020
Crescita Signs Exclusive Distribution Agreement with FILLMED
Jan 20, 2020
InMed First to Advance Cannabinol (CBN) into Therapeutic Clinical Trials
Jan 20, 2020
Armas Pharmaceuticals Adds Four Generic Injectables As First Launches of 2020
Jan 20, 2020
Global Injectable Drugs Delivery Industry
Jan 17, 2020
Women's HealthCare Market Worth $17.8 Billion by 2024 - Exclusive Report by MarketsandMarkets(TM)
Jan 17, 2020
Parkinson's Drug Market and Clinical Trial Insights Report, 2020-2025 - Availability, Dosage & Price Analysis on Levodopa/Carbidopa Therapeutics, Dopamine Agonist, MAO B Inhibitors, and More
Jan 17, 2020
Global Transdermal Patch Industry Outlook and Forecast 2020-2026: Dosage & Price Insights, Clinical Trials by Company, Drug Class, Indication & Patent Information
Jan 16, 2020
How Drone Technology is Helping Cultivators Increase Hemp Yield for CBD
Jan 14, 2020
New Head-to-Head Phase 3 Data Show SKYRIZI(TM) (risankizumab) Superior to Cosentyx® (secukinumab) Across Primary and All Ranked Secondary Endpoints in Adults with Moderate to Severe Plaque Psoriasis at 52 Weeks
Jan 14, 2020
CBD.market Noticed: Experienced CBD Consumers at a Loss; They Want To Know The Cost of 1mg CBD

Pages